» Articles » PMID: 37878

Elimination of Nadolol by Patients with Renal Impairment

Overview
Specialty Pharmacology
Date 1979 Jan 1
PMID 37878
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

1 Nadolol excretion was studied in 24 patients with chronic renal failure. 2 The amount of nadolol excreted during the 120-h period after receiving the drug ranged from less than 1% in functionally anephric, patients up to 11.5% in patients with average creatinine clearance of 57.9 +/- 3.6 ml/min/1.73 m2. 3 Renal clearance of nadolol was found to correlate with creatinine clearance; nadolol elimination is retarded in patients with renal failure. 4 Nadolol serum half-life is prolonged in proportion to the remaining renal function. Therefore, dosage intervals in renal patients receiving nadolol should be adjusted to creatinine clearance. 5 Haemodialysis effectively reduced serum concentration of the drug; it may therefore be a useful therapy for drug intoxication.

Citing Articles

A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia.

Kalsoom S, Rasool M, Imran I, Saeed H, Ahmad T, Alqahtani F Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399480 PMC: 10891759. DOI: 10.3390/ph17020265.


Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Bouchard J, Shepherd G, Hoffman R, Gosselin S, Roberts D, Li Y Crit Care. 2021; 25(1):201.

PMID: 34112223 PMC: 8194226. DOI: 10.1186/s13054-021-03585-7.


Cardiovascular drug therapy in the elderly: theoretical and practical considerations.

Williams B, Kim J Drugs Aging. 2003; 20(6):445-63.

PMID: 12710864 DOI: 10.2165/00002512-200320060-00004.


Bioequivalence of a highly variable drug: an experience with nadolol.

Buice R, Subramanian V, Duchin K Pharm Res. 1996; 13(7):1109-15.

PMID: 8842054 DOI: 10.1023/a:1016031313065.


The new beta-adrenergic antagonists.

Chung D, Laschuk M Can Anaesth Soc J. 1984; 31(4):430-3.

PMID: 6146393 DOI: 10.1007/BF03015419.


References
1.
Dreyfuss J, BRANNICK L, Vukovich R, Shaw J, Willard D . Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol. 1977; 17(5-6):300-7. DOI: 10.1002/j.1552-4604.1977.tb04609.x. View

2.
Ivashkiv E . Fluorometric determination of nadolol in human serum and urine. J Pharm Sci. 1977; 66(8):1168-72. DOI: 10.1002/jps.2600660831. View

3.
Lee R, Evans D, Baky S, LAFFAN R . Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression. Eur J Pharmacol. 1975; 33(2):371-82. DOI: 10.1016/0014-2999(75)90182-x. View

4.
Frithz G . Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension. Curr Med Res Opin. 1978; 5(5):383-7. DOI: 10.1185/03007997809111902. View

5.
Furberg B, Dahlqvist A, Raak A, Wrege U . Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris. Curr Med Res Opin. 1978; 5(5):388-93. DOI: 10.1185/03007997809111903. View